Showing 11-20 of 27 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Bringing Beta Cell Regenerative Therapy to the Clinic | Icahn School of Medicine at Mount Sinai | Andrew Stewart | Cures | 01-January-2024 to 31-December-2026 | $1,000,000.00 |
| Autoimmune stem-like T cells in type 1 diabetes | Memorial Sloan-Kettering Cancer Center | Andrea Schietinger | Cures | 01-September-2023 to 31-August-2026 | $750,000.00 |
| Market Analysis of Insulin Products Utilized by Patients With T1D & Pervasiveness of Insulin Caps | Milliman | Rebecca Smith | Transportfolio | 01-January-2025 to 31-December-2025 | $590,000.00 |
| Market Analysis of Devices Utilized By Patients With T1D & Eligibility For Future T1D Cell and Gene Therapies | Milliman | Rebecca Smith | Cures | 01-January-2025 to 31-October-2025 | $380,000.00 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2027 | $750,000.00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-December-2026 | $1,808,522.70 |
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643,550.00 |
| Project Equity | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-May-2024 to 30-April-2026 | $333,172.00 |
| Determining the role of SSTR2 on PRL-2903-mediated glucagon secretion | Trustees of Columbia University in the City of New York | Xiaojuan Chen | Improving Lives | 01-April-2026 to 31-March-2027 | $199,999.39 |
| Low level engraftment of modified HSCs for continuous and omnipresent autoantigen exposure as requirements to establish tolerance | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-June-2024 to 31-January-2026 | $188,704.16 |